Abbildung 31: Telmisartan - HCTZ
This was an 8-week study in 491 patients with mild-to-moderate hypertension who were non-responders (DBP 90 mmHg) in an open-label period of telmisartan 80 mg monotherapy.1 Patients were randomized to either continuation of monotherapy or fixed-dose combination with HCTZ 12.5 mg. After 8 weeks, mean DBP changes were -4.9 and -8.0 mmHg in the monotherapy and combination therapy groups, respectively (p<0.01). Mean SBP changes were -7.0 and -12.6 mmHg in the monotherapy and combination therapy groups, respectively (p<0.01). Most of the relative improvements with combination therapy occurred in the first 4 weeks. By endpoint, blood pressure was normalized (SBP/DBP <140/<90 mmHg) in 41.5% of patients on combination therapy and 26.1% of patients on monotherapy (P<0.05). 1. Lacourcière Y, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763–770.